Claims for Patent: 10,786,662

Summary for Patent: 10,786,662

Title:	Method of manufacturing microneedle and microneedle manufactured thereby
Abstract:	A method of manufacturing a microneedle according to the present disclosure includes a step of preparing a microneedle; a step of cooling the microneedle; and a step of inducing an endothermic reaction of the cooled microneedle, and coating the cooled microneedle with an active ingredient at least once. In accordance with such a configuration, coatability of the active ingredient can be improved due to an endothermic reaction without a separate drying process, thereby providing superior medication.
Inventor(s):	Baek; Seung Ki (Seoul, KR), Ahn; Myun Hwan (Namyangju-si, KR), Baek; Sun Young (Seoul, KR)
Assignee:	QuadMedicine (Seongnam-si, KR)
Application Number:	15/863,318
Patent Claims:	1. A method of manufacturing a microneedle, the method comprising: preparing a water-soluble microneedle; cooling the water-soluble microneedle; coating the cooled water-soluble microneedle with a water-soluble active ingredient at least once; after the cooled water-soluble microneedle is coated with the water-soluble active ingredient, waterproof-coating the microneedle with a waterproofing agent including a mineral-based substance or a lipid-based material; and drying the waterproof coated microneedle at a room temperature, wherein the cooling and the coating are sequentially performed under a vacuum or dry air condition without a separate drying process of the cooled water-soluble microneedle, a relative humidity in the cooling is 1% to 30%, and a relative humidity in the coating is 1% to 20%, wherein the cooling the water-soluble microneedle includes placing the water-soluble microneedle in a sealed cooling chamber and cooling the water-soluble microneedle while the water-soluble microneedle is placed in the sealed cooling chamber, wherein in the cooling, the microneedle is cooled by at least one rapid cooling method of a screw method, a piston method, a mono-pump method, a time-pressure method, a valve method, a spray method, a piezo method, an air-solenoid method, and an immersing the microneedle in a cooling substance, the cooling substance being at least one of liquid nitrogen, tetrafluoroethane, a Peltier element cooling fan, dry ice, wherein in the coating, the water-soluble microneedle is coated with the active ingredient by one of an electro-spinning coating method, an ultrasonic coating method, an atomization coating method, and a non-contact spray coating method, wherein in the coating, the water-soluble microneedle is coated, in a multilayer structure, with two or more active ingredients having same solubility, wherein in the waterproof-coating, an end portion or entire surface of the microneedle is coated with the waterproofing agent including the mineral-based substance or the lipid-based material by at least one of a dip-coating method, an atomization coating method, an electro-spinning coating method, and an ultrasonic coating method, and wherein the waterproofing agent includes at least one of beeswax, oleic acid, soy fatty acid, castor oil, phosphatidylcholine, vitamin E (d-.alpha.-tocopherol/Vitamin E), corn oil mono-di-tridiglycerides, cottonseed oil, olive oil, peanut oil, peppermint oil, safflower oil, sesame oil, soybean oil, hydrogenated vegetable oils, hydrogenated soybean oil, capric triglycerides (caprylic/capric triglycerides derived from coconut oil or palm seed oil) and phosphatidylcholine. 2. The method according to claim 1, wherein the preparing comprising: preparing a mold having a plurality of tip grooves; supplying a chemical liquid comprising at least a portion of a raw material or a biodegradable polymer ingredient to the mold to mold the microneedle; and removing the mold from the microneedle. 3. The method according to claim 2, wherein the mold comprises a polydimethylsiloxane (PDMS) mold and at least one of polyurethane, a metal, a biocompatible aluminum material, a water-soluble polymer, a lipophilic polymer, and an amphiphilic polymer, wherein the lipophilic polymer and the amphiphilic polymer comprise at least one of hydroxypropyl cellulose (HPC), hydroxypropyl methyl cellulose (HPMC), polycaprolactone (PCL), polyglycolide (PGA), polylactic acid (PLA), a polylactide-glycolide (PLGA) copolymer, polyvinylpyrrolidone (PVP), polyethylene glycol (PEG), polyethylene oxide (PEO), polypropylene oxide (PPO), poly(vinyl methyl ether) (PVME), poly(methyl acrylate) (PMA), propylene glycol, polyesteramide, polybutyric acid, acrylamide (acrylic amide), acrylic acid, hyaluronic acid (HA), and gelatin. 4. The method according to claim 2, wherein, in the supplying, the microneedle is molded through centrifugation and a polymer melting process after injecting the chemical liquid comprising the raw material in a low or high viscosity state into the mold. 5. The method according to claim 2, wherein the chemical liquid is formed of a biocompatible material and a water-soluble additive. 6. The method according to claim 5, wherein the biocompatible material comprises at least one of carboxymethyl cellulose (CMC), hyaluronic acid (HA), alginic acid, pectin, carrageenan, chondroitin sulfate, dextran sulfate, chitosan, polylysine, carboxymethyl chitin, fibrin, agarose, pullulan, polyanhydride, polyorthoester, polyetherester, polyesteramide, polybutyric acid, poly(valeric acid), polyacrylate, an ethylene-vinyl acetate polymer, acryl-substituted cellulose acetate, polyvinyl chloride, polyvinyl fluoride, polyvinyl imidazole, chlorosulphonate polyolefins, polyethylene oxide, polyvinylpyrrolidone (PVP), hydroxypropyl methyl cellulose (HPMC), ethyl cellulose (EC), hydroxypropyl cellulose (HPC), carboxymethyl cellulose, cyclodextrin, maltose, lactose, trehalose, cellobiose, isomaltose, turanose, and lactulose, or one or more of a copolymer of monomers forming this polymer and cellulose. 7. The method according to claim 6, wherein the water-soluble additive comprise at least one of trehalose, oligosaccharide, sucrose, maltose, lactose, cellobiose, hyaluronic acid, alginic acid, pectin, carrageenan, chondroitin sulfate, dextran sulfate, chitosan, polylysine, collagen, gelatin, carboxymethyl chitin, fibrin, agarose, polyvinylpyrrolidone (PVP), polyethylene glycol (PEG), polymethacrylate, hydroxypropyl methyl cellulose (HPMC), ethyl cellulose (EC), hydroxypropyl cellulose (HPC), carboxymethyl cellulose, cyclodextrin, and gentiobiose. 8. The method according to claim 1, wherein, in the coating, the active ingredient is coated up to one fifth or more of a height of the microneedle from an upper end of the microneedle. 9. The method according to claim 1, wherein, in the coating, a coating agent comprising a thickening agent, a biodegradable polymer resin, a water-soluble substance, and an active ingredient to be delivered to skin tissue is used. 10. The method according to claim 9, wherein the thickening agent comprises at least one of locust bean gum, rennet casein, dammer resin, glucosamine, glucomannan, guar gum, ghatti gum, carbomer, povidone, glycerin, carboxymethyl cellulose (CMC), hyaluronic acid, alginic acid, pectin, carrageenan, chondroitin sulfate, dextran sulfate, alginic acid, chitosan, karaya gum, polylysine, carboxymethyl chitin, fibrin, agarose, pullulan, polyanhydride, gellan gum, chitin, polyorthoester, microfibrillated, furcelleran, tragacanth gum, polyetherester, polyester amide, polybutyric acid, curdlan, polyvaleric acid, xanthan gum, polyacrylate, an ethylene-vinyl acetate polymer, acryl-substituted cellulose acetate, polyvinyl chloride, polyvinyl fluoride, tara gum, arabic gum, polyvinyl imidazole, psyllium seed gum, chlorosulphonate polyolefins, polyethylene oxide, polyvinyl pyrrolidone (PVP), chlorosulphonate polyolefins, hydroxypropyl methyl cellulose (HPMC), ethyl cellulose (EC), hydroxypropyl cellulose (HPC), carboxymethyl cellulose, cyclodextrin, maltose, lactose, trehalose, cellobiose, isomaltose, turanose, and lactulose, or at least one of a copolymer of monomers forming this polymer and cellulose. 11. The method according to claim 1, wherein the active ingredient comprises at least one of .alpha.-interferon, .beta.-interferon related to multiple sclerosis, interferon gamma, interleukin-1 alpha and beta, interleukin-3, interleukin-4, interleukin-6, interleukin-2, erythropoietin, follitropin .beta., follitropin .alpha., G-CSF, GM-CSF, human chorionic gonadotropin, signal transduction proteins, adherent proteins, luteinizing hormone, salmon calcitonin, glucagon, structural proteins, regulatory proteins, toxin proteins, cytokines, transcriptional regulatory factors, glucagon, blood coagulation factors, vaccines, enzyme inhibitors, a GNRH antagonist, insulin, human growth hormone, erythropoietin, filgrastin, heparin, low-molecular-weight heparin, and somatotropin. 12. The method according to claim 9, wherein the water-soluble substance is at least one of trehalose, oligosaccharide, sucrose, maltose, lactose, cellobiose, hyaluronic acid, alginic acid, pectin, carrageenan, chondroitin sulfate, dextran sulfate, chitosan, polylysine, collagen, gelatin, carboxymethyl chitin, fibrin, agarose, polyvinylpyrrolidone (PVP), polyethylene glycol (PEG), polymethacrylate, hydroxypropyl methyl cellulose (HPMC), ethyl cellulose (EC), hydroxypropyl cellulose (HPC), carboxymethyl cellulose, cyclodextrin, and gentiobiose. 13. The method according to claim 1, wherein the microneedle comprises a plurality of tips having a conical shape or a polygonal pyramid shape. 14. The method according to claim 1, wherein the method further includes evaporating a solvent from the coated microneedle.

Details for Patent 10,786,662

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	January 15, 1974	10,786,662	2037-01-05
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	December 27, 1984	10,786,662	2037-01-05
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 15, 1985	10,786,662	2037-01-05
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 16, 1990	10,786,662	2037-01-05
Bel-mar Laboratories, Inc.	CHORIONIC GONADOTROPIN	chorionic gonadotropin	Injection	017054	March 26, 1974	10,786,662	2037-01-05
Ferring Pharmaceuticals Inc.	A.P.L.	chorionic gonadotropin	For Injection	017055	December 13, 1974	10,786,662	2037-01-05
Fresenius Kabi Usa, Llc	CHORIONIC GONADOTROPIN	chorionic gonadotropin	For Injection	017067	March 05, 1973	10,786,662	2037-01-05